 OncLive | Noteworthy Research Spans Range of Malignancies OncLive Rituximab antibodies (turquoise) bind to the CD20 cell-surface markers on B-cells. A second paper reported the results of a most interesting phase III randomized trial that the Eastern Cooperative Oncology Group conducted to examine the potential ... |
